# Diabetes
<!-- toc -->
## Big Picture Diabetes Mellitus
**Problem: Hyperglycemia**
* T1DM -> NO insulin
* T2DM -> Not enough insulin and cells are not responding

**How can we fix this?**
* Replacement
  * **Insulins**
* Decrease glucagon and decrease gastric emptying
  * **Incretin Analogues (i.e.Exenalide)**
  * **Amylin Analogues (1.e. Pramlintide)**
* Inhibit breakdown of endogenous incretins
  * **DDP IV inhibitors (i.e. Sitagliptin)**
* Stimulate glucose uptake and inhibit liver gluconeogenesis
  * **Metformin**
* Increase insulin release (Secretagogues)
  * **Sulfonylureas (i.e. glipizide)**
  * **Meglitinides (i.e. Repaglinide)**
* Inhibit glucose absorption from intestine
  * **Alpha Glucosidase inhibitors (i.e. Acarbose)**
* Inhibit glucose reabsorption from kidney
  * **SGLT 2 inhibitors (i.e. Canaglifiozin)**
* Synthesize cells to insulin effects
  * **Thiazolidinediones (i.e. Pioglitazone)**

## Insulin
**MOA**: **Binds insulin receptor - Tyrosine Kinase phosphorylation**

Physiologic insulin release
* Basal & Postprandial insulin
* **Goal of feplacement is to mimic physiological response**

*Insulin classification according to onset and duration*
* Rapid acting: 5-15 min lasts 2-4 hours
* Short acting: 30-60 min lasts 3-6 hours
* Intermediate: 2-4 hours lasts 10-12 hours
* Long acting: 1-2 hours lasts 12-24 hours

**Side Effects:**
* **Hypoglycemia & Weight Gain**
* Lipohypertrophy or Lipoatrophy
* Hypokalemia

### Types
1. Rapid Action - **Aspart, Lispro, Glulisine**
* Subcutaneous (Subq) only
* Use: Prandial coverage for DM1, DM2, Gestational DM
2. Short Acting - **Regular Insulin**
* Subcutaneous or *IV* Use
* Subg- Prandial coverage for DM1, DM2, Gestational DM
* **IV-DKA**
* IV-Hyperkalemia
  * Stimulates Na-K ATPase
  * Shortterm
3. Intermediate Acting - **Insulin NPH (N)**
* Subcutaneous only
* Basal coverage
4. Long Acting - **Detemir, Glargine**
* Subcutaneous only
* Basal coverage- give once or twice daily

## Incretin & Amylin Analogues
### Incretin Analogues
**Exenatide (Subq)**

*Incretin Hormones*
* Released from beta cells of pancreas in response to oral glucose (not IV glucose)
* **Increase insulin release, slow gastric emptying, inhibit glucagon release. increases satiety**
* 2 hormones
  * **Glucagon like peptide (GLP 1)**
  * Gastric inhibitory peptide (GIP)
* Degraded by dipeptidyl peptidase IV (DPP-IV)

**Exenatide**
* **Came originally from Lizard Spit**
* Use: Adjunct in **DM2, Weight Loss in DM2 (Subgq only)**
* SE: **Pancreatitis**
* **Low risk Hypoglycemia**

### Amylin Analogue
**Pramlintide (Subq)**

*Amylin Hormone*

* **Actions:**
  * Secreted with insulin from Beta cells
  * **Slows gastric emptying, Decreases glucagon release, Postprandial glucose control**

**Pramlintide (Analogue)**
* Use: Adjunct in DM1 & Adjunct in DM2
* Subq only
* SE: Gaslroparesis, **Hypoglycemia**
* **Weight Loss**

## Oral Hypoglycemics
### Metformin

*AMPK Activator*

**MOA:**
* Activates 5-AMP protein kinase
  * AMPK is a protein kinase thal responds to increased stress and energy demands
* Stimulates peripheral glucose uptake, Inhibits liver gluconeogenesis, **Increases insulin sensitivity**
* **No Hypoglycemia**

**Use**
* **Pre-Diabetes, *First line DM2*, Weight loss DM2**, Polycystic ovary syndrome (Insulin resistance)

**SE**
* **Modest weight loss**
* *Rare Lactic acidosis in renal failure (Avoid in Renal Failure)*- Inhibits mitochondrial enzymes
* **Significant Diarrhea**

### Sulfonylureas

**1st Gen - Chlorpropamide**

**2nd Gen - Glipizide, Glyburide, Glimepiride**

**MOA:**
* Closes ATP sensitive K channel, *decreases K conductance* - > **Cell is depolarized, leading
to opening Ca channels, Ca causes fusion of insulin granules with cell membrane**

**Use:**
* Early stages DM2 in addition to Metformin
* Needs some islet cell function (No DM1 or late DM2)

**SE**
* **Hypoglycemia if missed meals**
* **Weight gain**
* Disulfiram reaction (Chlorpropamide)

### Alpha glucosidase inhibitors
**Acarbose & Miglitol**

**MOA:**
* Inhibits brush border alpha-glucosidase in small intestine
* Decrease CHO hydrolysis (Starch and disaccharides to glucose)
* **Decrease Postprandial hyperglycemia**

Use: Adjunct in DM2

Weight Neutral & Low Hypoglycemia risk

Administration: Take with first bite of meal

**SE**
* **GI disturbance**
* **Liver toxicity**

### Meglitinides (suffix glinide)

**Repaglinide (Oral)**
**MOA:**
* **Decreases K conductance -> Stimulates insulin release**
* Different site than sulfonylureas but same idea)

**Use**: Monotherapy or adjunct in DM2 **(postprandial hyperglycemia)**

**SE:** **Hypoglycemia & Weight Neutral**

### Thiazolidinediones (Suffix -glitazone)
**Pioglitazone & Rosiglitazone (Oral)**

**MOA:**
* Activate PPAR-Gamma nuclear transcription regular
* Increases insulin sensitivity in tissue

Use: Adjunct in DM2

SE:
* Weight gain & Low risk Hypoglycemia
* Edema and fracture risk
* **MI risk (Rosiglitazone)**
* ***BLACK BOX WARNING: Contraindicated in CHF***

### DDP IV Inhibitors (suffix-gliptin)
**Sitagliptin & Saxagliptin (Oral)**

MOA
* Inhibits Dipeptidyl Peptidase IV (DPP IV)
* DDP IV is responsible for degrading endogenous incretins (GLP1, GIP)

Use: Adjunct in DM2

SE: **Pancreatitis, Weight neutral & Low risk hypoglycemia**

### SGLT2 Inhibitors
**Canagliflozin (Oral)**
MOA: Blocks glucose reabsorption in PCT

Use: DM2

SE: **Glucosuria, UTI, Dehydration, Polydipsia**

## Hyperglycemic Agents
### Diazoxide
MOA: **Increases open time of K channel- inhibits insulin release**. Opposite MOA of sulfonylureas

Use: **Insulinoma**
SE: Na/H20 retention

### Glucagon (Synthetic)
MOA: cAMP/IP3/Increase Intracellular Ca Pathway

Use
* Hypoglycemia
* **Beta Blocker overdose**
  * Antagonize BB decrease of cAMP/Ca
  * Increases contractility
* Diagnosis of Pheochromocytoma
  * Release of catecholamines

**SE: Vomiting after giving dose**

### Algorithm for hypoglycemia
*Normal mental status*: **Oral glucose**

*Altered mental status*:
* Patient has IV access
  * Give IV glucose
* Patient has No IV access
  * Give IM glucagon

*Insulinoma*: **Diazoxide**

## Diabetes Summary and Treatment
### DM1

1. Strategy 1
* Basal insulin (Glargine, Detemir)
* Fast acting with meals (Aspart, Regular)

2. Strategy 2
* Intermediate acting (NPH) combined in the same dose with fast acting (aspart or regular)
* Given twice daily

3. Strategy 3
* Insulin pump
* Delivers basal and boluses with meals
* Aspart or regular

### BOTH DM 1 and DM2

* Acute Hospitalization -> **Insulin, No Oral Agents**
* Dyslipidemia
  * Statin
* Prevent Diabetic nephropathy
  * ACE or ARB

### DM2
* Various guidelines
* Depends on A1C & Patient specific characteristics

*Step 1*

Lifestyle PLUS Metformin

Step 2
* Add Insulin
* Sulfonylureas
* DDP IV inhibitors
* SGLT 2 inhibitors
* Alpha Glucosidase
* Incretins or Amylins

## Treatment of Hyperkalemia
### Short term
* **IV Insulin Plus Dextrose**
  * (Pushes K inside cells using Na-K ATPase)
* **Sodium Bicarbonate IV**
  * (Correct acidosis and exchanges extracellular K for intracellular H)
* **Albuterol Inhaled** (Adrenergic agonist)
  * Stimulate Na-K ATPase
* **Calcium IV**
  * Stabilize cardiac membrane and prevent arrhythmia if there's EKG changes
### Intermediate term
* **Sodium polystyrene - Oral**
  * Binds K in colon and increase secretion
* Furosemide IV
  * Increase renal excretion of K
### Longterm
* Dialysis
* Fix underlying cause
